NasdaqGS:EXELBiotechs
Will Strong Q3 Results and $750M Buyback Shift Exelixis' (EXEL) Outlook?
Exelixis reported strong third quarter results, raised its earnings guidance for 2025, and announced a new US$750 million share repurchase program, following a series of operational updates and executive changes that included a new General Counsel appointment this November.
Investor attention was drawn by the combination of improved financial performance, increased revenue outlook, and substantial capital return commitments.
We'll examine how the upgraded financial guidance and share buyback...